to-BBB Further Strengthens Supervisory Board with Dr. Peter Høngaard Andersen
to-BBB announced the addition of Dr. Peter Høngaard Andersen to its Supervisory Board. Dr. Andersen brings many years of pharma drug development experience to the Board. His experience and strategic guidance will be instrumental to further build to-BBB as a leading company in brain drug development.
Dr. Peter Høngaard Andersen is currently the Sr. VP Global Public Affairs and Corporate Patents & Trademarks at Lundbeck, the Danish global pharma company focused on brain diseases. He previously held multiple senior R&D positions for Lundbeck and Novo Nordisk. Dr. Andersen holds degrees in chemistry, biochemistry and medicine from University of Copenhagen. He currently holds Board seats at Epitherapeutics and at Prexton Therapeutics, as well as board positions for the European pharmaceutical industry (EFPIA and IMI).
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.